MANILA, Philippines — Singapore Diagnostics (SGD), the Philippine flagship of Pathology Asia and one of the country’s leading private laboratories, has won eight national and regional healthcare honors from 2023 to 2025, cementing its position as a consistent industry champion.
SGD recently secured its third consecutive Diagnostics Provider of the Year award at the 2025 Healthcare Asia Awards. The company now operates 60 laboratory sites and supports over two million patients annually across the Philippines.
2025 Triple Win
The 2025 ceremony delivered three major recognitions for SGD:
- Diagnostics Provider of the Year (third consecutive win)
- ICT Initiative of the Year for its Electronic Single Laboratory Integration Platform (e-SLIP), connecting over 800 partner laboratories nationwide and improving turnaround times while reducing administrative errors
- Facilities Improvement Initiative of the Year for transforming VisayasMed’s laboratory in Cebu, resulting in sixfold increased diagnostic capacity and notably shortened turnaround times
Building on Success
These victories build on SGD’s 2024 wins for Employee Engagement of the Year and Service Innovation of the Year, recognizing its culture of upskilling and continuous improvement systems.
In 2023, SGD earned its first Diagnostics Provider of the Year award and was named a Philippine Growth Champion by Statista and Philippine Daily Inquirer, placing among the country’s Top 25 fastest-growing companies.
Quality Standards
Since 2019, SGD has maintained accreditation from the College of American Pathologists (CAP)—the global gold standard in laboratory quality assurance—ensuring all testing follows strict international benchmarks.
These achievements position SGD as a trusted healthcare partner combining medical expertise, technology, and operational excellence to advance Philippine diagnostics through innovation and accessibility.
More information: www.singaporediagnostics.com
